Li Shan Chiu
BForensics/BSc, BMedSc (Hons), PhD
Li Shan Chiu is a Research Assistant in the Hearing Therapeutics group evaluating the therapeutic efficacy of anti-fibrotic agents in cochlear implant-induced fibrosis.
She completed her PhD at UWA in 2019 with a thesis entitled Examining the neuroprotective efficacy of arginine-rich peptides in a traumatic brain injury model. This contributed to the development of a novel neuroprotective peptide with promising commercial potential. Li Shan joined ESIA in November 2020, bringing her experience in molecular and cellular biology techniques and animal handling skills to the team.
Areas of research
- Wound healing, tissue repair & fibrosis
Chiu LS, Anderton RS, Cross JL, Clark VW, Edwards AB, Knuckey NW, Meloni BP. Assessment of R18, COG1410, and APP96-110 in Excitotoxicity and Traumatic Brain Injury. Translational neuroscience. 2017 Nov 15;8:147-57.
Chiu LS, Anderton RS, Knuckey NW, Meloni BP. Peptide pharmacological approaches to treating traumatic brain injury: a case for arginine-rich peptides. Molecular neurobiology. 2017 Dec;54(10):7838-57. https://link.springer.com/article/10.1007/s12035-016-0287-3
Chiu LS, Anderton RS, Knuckey NW, Meloni BP. The neuroprotective potential of arginine-rich peptides for the acute treatment of traumatic brain injury. Expert review of neurotherapeutics. 2016 Apr 2;16(4):361-3. https://www.tandfonline.com/doi/full/10.1586/14737175.2016.1150180
Chiu LS, Anderton RS, Cross JL, Clark VW, Knuckey NW, Meloni BP. Poly-arginine peptide R18D reduces neuroinflammation and functional deficits following traumatic brain injury in the long-Evans rat. International Journal of Peptide Research and Therapeutics. 2019 Dec;25(4):1563-72. https://link.springer.com/article/10.1007/s10989-018-09799-8
Chiu LS, Anderton RS, Clark VW, Knuckey NW, Mardon K, Bhalla R, South SM, Meloni BP. Tissue distribution of intravenously administrated poly-arginine peptide R18D in healthy male Sprague–Dawley rats. Future Drug Discovery. 2020 Mar 30;2(2):FDD37.